Company intelligence / Profile preview

Regenelead Therapies

Shanghai, Shanghai, Chinaregenelead.com ↗

Ownership: Private
Development stage: Other

Overview

Regenelead Therapies is a China-based biotech with a clinical-stage pipeline covering gene therapy, biologicals, and immunotherapies focused on neurodegeneration, vascular disease, oncology, and ophthalmology. Its programs are in early- to mid-clinical development (Preclinical to Phase 2); key data on safety and preliminary efficacy being generated, but no pivotal or commercial-stage results yet[2][3][1].

Therapeutic areas: OncologyNeurologyOphthalmologyCardiovascular
Modalities: Biological productsAAV based gene therapyTherapeutic vaccinemRNA vaccineMonoclonal antibody
Industry: Biotech

Drug pipeline

7 assets

RGL-2102

6 more assets in the full pipeline.

Partnerships

Guangdong General Hospital (clinical collaborator on mRNA cancer vaccine/NSCLC)[2]Fudan University (collaborator on pancreatic cancer vaccine study)[2]

Beyond the preview

Go deeper on Regenelead Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenelead Therapies.